ArticleEuropean journal of medical research2025
Tracheobronchial adenoid cystic carcinoma: a two-center retrospective analysis of clinical features and survival outcomes.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTracheobronchial adenoid cystic carcinoma (TACC) is an uncommon gland-type tumor. While prior studies have addressed its clinical features and prognosis, evidence from larger cohorts remains scarce.
methodsTACC patients treated at Dongzhimen Hospital (DZM) and Emergency General Hospital (EG) between 2010 and 2023 were enrolled. Survival curves were plotted using the Kaplan-Meier method before and after propensity score matching (PSM). The key variables were screened by LASSO regression, and predictive and interaction analysis was done by multifactor Cox regression and accelerated failure time (AFT) models. Overall survival (OS) was the study endpoint.
resultsThe median age of 169 TACC patients (EG 144, DZM 25) was 47.8 ± 13.2 years, 50.9% were female, and 79.9% of patients had not undergone surgery. The median follow-up was 67.5 months (interquartile range [IQR] 42.2-105.8). Survival at 5, 10, and 15 years was 68.0%, 32.4%, and 17.1%, respectively. The median survival time was 88 months. Multifactorial Cox regression analysis found initial tumor extension (ITE) (HR: 1.28, 95% CI 1.12-1.47; P = 0.000), surgery (HR: 0.36, 95% CI 0.20-0.64; P = 0.000), and photodynamic therapy (PDT) (HR: 0.46, 95% CI 0.22-0.97; P = 0.042) to be independent prognostic factors; this was re-affirmed by AFT model. Survival was extended by surgery combined with PDT, but the interaction was nonsignificant.
conclusionThis study identified ITE as the independent prognostic factor. Surgery is the key to the prognosis, and PDT and its combination with surgery may enhance patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.